Updated to include additional earnings reports, including CVS Health.

If you'd like to receive "5 Things" in your email inbox every morning, please register for TheStreet Alerts and follow me.

Here are five things you must know for Tuesday, Nov. 8:

1. -- Stock futures were lower on Tuesday as voters in the U.S. headed to the polls to elect the country's next president.

Stocks rebounded from a nine-day losing streak on Monday, posting the biggest gains in eight months, as confidence in an election win for Democratic presidental candidate Hillary Clinton over her Republican rival Donal Trump inspired market bulls.

Shares in Europe and Asia traded cautiously ahead of the U.S. election.

The economic calendar in the U.S. on Tuesday includes the Job Openings and Labor Turnover Survey for September at 10 a.m. EST.

2. -- U.S. state attorneys general have joined a federal antitrust probe of the planned merger between DuPont (DD) and Dow Chemical  (DOW) , Reuters reported, citing three people familiar with the matter, while a separate group of state attorneys general are expected to join a probe of Bayer's $66 billion deal to buy Monsanto  (MON) .

About seven states, including California, have joined the probe of Dow's planned merger with DuPont. It wasn't yet clear how many states would join the Bayer-Monsanto merger investigation, one source said.

The states are concerned that the companies may raise pesticide and herbicide prices for farmers following a merger, and have less incentive to compete to introduce better and cheaper products, two of the sources told Reuters.

DuPont and Dow said in separate statements they expected to gain approval for their deal. "In the U.S., we are working constructively with federal and state regulatory authorities, elected officials and all agriculture stakeholders to show the pro-competitive benefits of the merger," the companies said.

Dow Chemical is a holding in Jim Cramer's Action Alerts PLUS Charitable Trust Portfolio. Want to be alerted before Cramer buys or sells DOW? Learn more now.

3. -- Two leaders of the Senate Judiciary Committee have called for the Federal Trade Commission to review whether EpiPen maker  Mylan ( MYL) engaged in anticompetitive practices.

Committee chairman Sen. Charles Grassley (R., Iowa) and Sen. Patrick Leahy (D., Vt.) said in a letter to the FTC that the agency should look into issues including school contracts that restricted purchases of EpiPen competitors, The Wall Street Journal reported. 

Mylan officials didn't  immediately respond to requests for comment from the Journal on Monday. 

Mylan has been heavily criticized for a more-than-sixfold price increase in the EpiPen since it bought the product in 2007.

4. -- Toyota (TM) , the world's top-selling automaker, said a stronger yen in the July-September quarter led to a profit decline of 36%.

Sales fell 9% to 6.48 trillion yen ($62.3 billion).

Toyota, the maker of the Prius hybrid, Camry sedan and Lexus luxury models, is more exposed to swings in foreign exchange because it produces two-fifths of its vehicles in Japan, half of which it exports, according to Reuters.

Toyota said it expects to sell 10.1 million vehicles worldwide through March 2017, including sales by affiliates.

The automaker raised its annual profit forecast to 1.5 trillion yen from an earlier 1.45 trillion yen. Last year, it earned 2.3 trillion yen
 
5. -- Priceline ( PCLN) posted third-quarter earnings and revenue that topped analysts' forecasts and said it would scale back its restaurant booking site, OpenTable.

The stock was rising 5.3% in premarket trading.

Valeant Pharmaceuticals (VRX)  reported third-quarter adjusted earnings of $1.55 a share, below analysts' forecasts of $1.75, and cut its guidance for the year.

The Canadian company said it expects adjusted earnings of $5.30 to $5.50 a share on revenue of $9.55 billion to $9.65 billion. Valeant previously guided to earnings of $6.60 to $7 a share for the year on revenue of $9.9 billion to $10.1 billion. 

The stock tumbled 8% in premarket trading.

CVS Health (CVS)  said third-quarter adjusted earnings were $1.64 a share, 7 cents above forecasts. But the company reduced its full-year adjusted earnings outlook to $5.77 to $5.83 a share.

CVS shares fell 13% in premarket trading.

More from Futures

Big Banks Pass the Stress Tests and 4 Other Stories to Watch Friday Morning

Big Banks Pass the Stress Tests and 4 Other Stories to Watch Friday Morning

Futures Fall on Further Trade Rhetoric from China and 4 Other Stories to Watch

Futures Fall on Further Trade Rhetoric from China and 4 Other Stories to Watch

GE Loses Its Spot on the Dow and 4 Other Stories to Watch Wednesday Morning

GE Loses Its Spot on the Dow and 4 Other Stories to Watch Wednesday Morning

Trump Threatens More Tariffs and 4 Other Stories to Watch Tuesday Morning

Trump Threatens More Tariffs and 4 Other Stories to Watch Tuesday Morning

Google Invests $550 Million in JD.com and 4 Other Stories to Watch Monday

Google Invests $550 Million in JD.com and 4 Other Stories to Watch Monday